Emcure Pharmaceuticals rises on BOB Capital's bullish initiation, Sanofi tie-up

Emcure Pharmaceuticals

03/10/2025 06:46

** Emcure Pharmaceuticals' EMCU.NS stock rises 2.2% to 1,333 rupees after BOB Capital initiates "buy" rating

** Brokerage sets 1,530 rupees PT, implying 20% upside on domestic recovery, Sanofi portfolio integration

** Says EMCU immune to U.S. tariff concerns after demerging American unit Avet Lifesciences, retains only Canada presence

** EMCU and Sanofi India announced distribution partnership in July to expand therapy portfolio

** BOB estimates cardiovascular therapy will become top contributor at 20.8% of sales post-integration vs gynecology previously

** Expects domestic sales boost from FY26-28 driven by portfolio expansion

** EMCU down 9.9% YTD vs Nifty 500's .NIFTY500 2.5% gain

 (Reporting by Bharath Rajeswaran in Bengaluru)

 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))